No connection

Search Results

MED

BEARISH
$10.92 Live
Medifast, Inc. · NYSE
Target $12.0 (+9.9%)
$9.22 52W Range $15.46

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 30, 2026
Market cap
$120.47M
P/E
N/A
ROE
-9.1%
Profit margin
-4.8%
Debt/Equity
0.05
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
90%
Medifast exhibits severe operational distress, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic YoY EPS decline of 1750%. While the company maintains a fortress balance sheet with very low debt (Debt/Equity 0.05) and high liquidity (Current Ratio 4.69), these strengths are overshadowed by a collapsing top line (-36.9% revenue growth). The stock is trading at a deep discount to book value (P/B 0.57), but the fundamental trajectory suggests a 'value trap' rather than a recovery opportunity.

Key Strengths

Extremely low leverage (Debt/Equity 0.05)
Strong liquidity position (Current Ratio 4.69)
High Gross Margins (71.33%)
Trading significantly below book value (P/B 0.57)
Low Price-to-Sales ratio (0.31)

Key Risks

Severe revenue contraction (-36.9% YoY)
Catastrophic earnings collapse (-1750% YoY EPS growth)
Negative operating and profit margins
Long-term price destruction (-94.6% over 5 years)
Bearish technical trend (0/100 score)
AI Fair Value Estimate
Based on comprehensive analysis
$10.0
-8.4% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
23
Weak
Value
50
Future
10
Past
15
Health
40
Dividend
0
AI Verdict
Value Trap
Key drivers: Revenue collapse, Negative earnings trajectory, Piotroski F-Score 2/9, Strong balance sheet providing a temporary floor
Confidence
90%
Value
50/100

Trades at a deep discount to assets, but lacks earnings power.

Positives
  • P/B of 0.57
  • P/S of 0.31
Watchpoints
  • Negative Forward P/E
  • Lack of earnings to support valuation
Future
10/100

Growth metrics are in a state of freefall.

Positives
No standout positives identified.
Watchpoints
  • -36.9% Revenue Growth
  • -1750% EPS Growth
Past
15/100

Consistent long-term value destruction.

Positives
No standout positives identified.
Watchpoints
  • -94.6% 5-Year Change
  • -87.5% 3-Year Change
Health
40/100

Balance sheet is healthy, but operational health is critical.

Positives
  • Low Debt/Equity
  • High Quick Ratio
Watchpoints
  • Piotroski F-Score 2/9
  • Negative ROE/ROA
Dividend
0/100

No income component to the investment.

Positives
No standout positives identified.
Watchpoints
  • No dividend yield
  • 0/100 Dividend Strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$10.92
Analyst Target
$12.0
Upside/Downside
+9.9%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for MED and closest competitors.

Updated 2026-04-29
MED
Medifast, Inc.
Primary
5Y
-94.6%
3Y
-87.5%
1Y
-12.6%
6M
-10.3%
1M
+9.3%
1W
-0.3%
BSE
Bassett Furniture Industries, Incorporated
Peer
5Y
-27.8%
3Y
+2.9%
1Y
-5.0%
6M
-10.1%
1M
-1.2%
1W
-1.6%
DLT
Duluth Holdings Inc.
Peer
5Y
-80.0%
3Y
-50.9%
1Y
+95.8%
6M
-7.8%
1M
+50.9%
1W
+4.1%
GHG
GreenTree Hospitality Group Ltd.
Peer
5Y
-88.8%
3Y
-71.3%
1Y
-41.1%
6M
-41.4%
1M
+3.4%
1W
-2.0%
BRL
Brilliant Earth Group, Inc.
Peer
5Y
-91.7%
3Y
-66.5%
1Y
-2.2%
6M
-49.4%
1M
-14.8%
1W
-5.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-3.96
PEG Ratio
0.97
P/B Ratio
0.57
P/S Ratio
0.31
EV/Revenue
-0.11
EV/EBITDA
-1515.42
Market Cap
$120.47M

Profitability

Profit margins and return metrics

Profit Margin -4.84%
Operating Margin -10.39%
Gross Margin 71.33%
ROE -9.13%
ROA -3.34%

Growth

Revenue and earnings growth rates

Revenue Growth -36.9%
Earnings Growth N/A
Q/Q Revenue Growth -36.9%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.05
Low debt
Current Ratio
4.69
Strong
Quick Ratio
3.89
Excellent
Cash/Share
$16.22

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.1B
Gross Margin
69.4%
Op. Margin
-10.4%
Net Margin
-24.1%
Total Assets
$0.2B
Liabilities
$0.0B
Equity
$0.2B
Debt/Equity
0.25x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
126%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-04
$N/A
2026-02-17
$-1.65
-101.2% surprise
2025-11-03
$-0.21
+41.7% surprise
2025-08-04
$0.22
+215.8% surprise

Consumer Cyclical Sector Comparison

Comparing MED against 430 companies in the Consumer Cyclical sector (26 bullish, 155 neutral, 249 bearish)
Return on Equity (ROE)
-9.13%
This Stock
vs
-50.12%
Sector Avg
-81.8% (Below Avg)
Profit Margin
-4.84%
This Stock
vs
-5.66%
Sector Avg
-14.4% (Weaker)
Debt to Equity
0.05
This Stock
vs
1.6
Sector Avg
-96.6% (Less Debt)
Revenue Growth
-36.9%
This Stock
vs
26.54%
Sector Avg
-239.0% (Slower)
Current Ratio
4.69
This Stock
vs
2.51
Sector Avg
+87.0% (Stronger)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

CHARD DANIEL R
Chief Executive Officer
Stock Award
2026-03-25
41,795 shares
MALONEY JAMES P.
Chief Financial Officer
Stock Award
2026-03-25
35,358 shares
MACKENZIE JONATHAN BARRETT
Officer
Stock Award
2026-03-25
10,830 shares
CHARD DANIEL R
Chief Executive Officer
Buy
2026-03-20
17,678 shares · $178,725
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

DEF 14A
DEF 14A
2026-04-06

MED filed a Definitive Proxy Statement on April 6, 2026, providing shareholders with necessary information and voting materials for an upcoming meeting.

8-K
8-K
2026-03-20
10-K
10-K
2026-02-17

MED submitted its annual 10-K filing on February 17, 2026, which includes standard disclosures regarding its business operations, financial condition, and risk factors. While specific financial metrics were not provided in the excerpts, the filing contains detailed analysis within the MD&A and Risk Factors sections.

8-K
8-K
2026-02-17

MED likely filed this 8-K to announce its annual financial results for the fiscal year ended December 31, 2025.

8-K
8-K
2026-01-05
10-Q
10-Q
2025-11-03

MED filed its quarterly 10-Q report on November 3, 2025. The company reported no material changes to its risk factors since the filing of its 2024 Form 10-K. No specific financial highlights were provided in the available excerpts.

8-K
8-K
2025-11-03

MED filed an 8-K on November 3, 2025, likely to announce its third-quarter financial results.

10-Q
10-Q
2025-08-04

MED submitted its 10-Q filing on August 4, 2025, though specific financial performance metrics were not provided in the available excerpts. The company reported that there have been no material changes to the risk factors previously disclosed in its 2024 Form 10-K.

8-K
8-K
2025-08-04

MED filed an 8-K on August 4, 2025, likely to announce its second-quarter financial results.

8-K
8-K
2025-06-20
DEF 14A
DEF 14A
2025-04-29
10-Q
10-Q
2025-04-28
8-K
8-K
2025-04-28
10-K
10-K
2025-02-18
8-K
8-K
2025-02-18
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
NONE
1 analysts
Stephens & Co.
2026-02-19
Maintains
Equal-Weight Equal-Weight

Past News Coverage

Recent headlines mentioning MED from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI Chat
Markets
Profile